Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1checkpoint-defective neuroblastoma

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis

(2009) T Van Maerken et al.   CELL DEATH AND DIFFERENTIATION

Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study

(2009) Caroline Laverdière et al.   JNCI-Journal of the National Cancer Institute

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

MDM2SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

(2009) Chiara Perfumo et al.   PEDIATRIC BLOOD & CANCER

Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients

(2008) S. Cattelani et al.   CLINICAL CANCER RESEARCH

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

(2008) Susan Ashwell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS